Lee, So Jin Kim, Min Ju Kwon, Ick Chan Roberts, Thomas M. 2024-01-20T03:31:57Z 2024-01-20T03:31:57Z 2022-01-25 2016-09 0169-409X https://pubs.kist.re.kr/handle/201004/123701 Small interfering RNA (siRNA) has gained attention as a potential therapeutic reagent due to its ability to inhibit specific genes in many genetic diseases. For many years, studies of siRNA have progressively advanced toward novel treatment strategies against cancer. Cancer is caused by various mutations in hundreds of genes including both proto-oncogenes and tumor suppressor genes. In order to develop siRNAs as therapeutic agents for cancer treatment, delivery strategies for siRNA must be carefully designed and potential gene targets carefully selected for optimal anti-cancer effects. In this review, various modifications and delivery strategies for siRNA delivery are discussed. In addition, we present current thinking on target gene selection in major tumor types. (C) 2016 Elsevier B.V. All rights reserved. English ELSEVIER Delivery strategies and potential targets for siRNA in major cancer types Article 10.1016/j.addr.2016.05.010 1 ADVANCED DRUG DELIVERY REVIEWS, v.104, pp.2 - 15 ADVANCED DRUG DELIVERY REVIEWS 104 2 15 N scie scopus 000381239300002 2-s2.0-84973527084 Pharmacology & Pharmacy Pharmacology & Pharmacy Review SMALL INTERFERING RNA IN-VIVO DELIVERY NANOPARTICLE-BASED DELIVERY PROTEIN-KINASE CK2 BREAST-CANCER SYSTEMIC DELIVERY OVARIAN-CANCER HEPATOCELLULAR-CARCINOMA POLYMERIZED SIRNA TUMOR-GROWTH Small interfering RNA (siRNA) Delivery strategy of siRNAs Cancer siRNA therapeutics Gene target